Bargain Priced Viatris Reports Strong Q3 Earnings Results

seekingalpha11-09

Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%.Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482543236?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182148632/image_182148632.jpg","is_english":true,"pubTime":"2024-11-09 03:36","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2482543236","market":"us","top_or_hot":-1,"title":"Bargain Priced Viatris Reports Strong Q3 Earnings Results","media":"seekingalpha","content":"<div>\n<p>Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%.Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with ...</p>\n\n<a href=\"https://seekingalpha.com/article/4735098-bargain-priced-viatris-reports-strong-q3-earnings-results\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bargain Priced Viatris Reports Strong Q3 Earnings Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBargain Priced Viatris Reports Strong Q3 Earnings Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 03:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4735098-bargain-priced-viatris-reports-strong-q3-earnings-results><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%.Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with ...</p>\n\n<a href=\"https://seekingalpha.com/article/4735098-bargain-priced-viatris-reports-strong-q3-earnings-results\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTRS","symbol_name":"Viatris Inc.","start_time":0,"source_url":"https://seekingalpha.com/article/4735098-bargain-priced-viatris-reports-strong-q3-earnings-results","article_id":"2482543236","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182148632/image_182148632.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482543236","pubTimestamp":1731094606,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%.Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with greater than average product launches due to the Inflation Reduction Act.Recent earnings show revenue stabilization, driven by successful new product launches, with fewer divestitures moving forward.With a stronger balance sheet and increased capital for business development, Viatris is well-positioned for share-price appreciation and dividend growth.Viatris remains a strong buy due to new product launches, a bargain valuation at 5x forward earnings, and significant debt reduction to 3x EBITDA by year's end.   duckycards  Six months back, I wrote an article recommending Viatris  as a strong buy due to a spate of coming generic pharmaceutical launches. The investment thesis centered on the reduced patent exclusivity for small molecule drugs provided","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"VTRS":"Viatris Inc."},"translate_title":"价格低廉的Viatris报告强劲的第三季度盈利结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":0.9},"content_text":"Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%.Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with greater than average product launches due to the Inflation Reduction Act.Recent earnings show revenue stabilization, driven by successful new product launches, with fewer divestitures moving forward.With a stronger balance sheet and increased capital for business development, Viatris is well-positioned for share-price appreciation and dividend growth.Viatris remains a strong buy due to new product launches, a bargain valuation at 5x forward earnings, and significant debt reduction to 3x EBITDA by year's end.   duckycards  Six months back, I wrote an article recommending Viatris (NASDAQ:VTRS) as a strong buy due to a spate of coming generic pharmaceutical launches. The investment thesis centered on the reduced patent exclusivity for small molecule drugs provided","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"analysis","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482543236"}